JP6986445B2 - １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 - Google Patents

１５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 Download PDF

Info

Publication number
JP6986445B2
JP6986445B2 JP2017527848A JP2017527848A JP6986445B2 JP 6986445 B2 JP6986445 B2 JP 6986445B2 JP 2017527848 A JP2017527848 A JP 2017527848A JP 2017527848 A JP2017527848 A JP 2017527848A JP 6986445 B2 JP6986445 B2 JP 6986445B2
Authority
JP
Japan
Prior art keywords
hepe
fibrosis
pharmaceutical composition
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017527848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536380A (ja
JP2017536380A5 (enExample
Inventor
ロウエ ジョナサン
ダッフィ ケビン
クリマク ジョン
Original Assignee
アフィミューン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィミューン リミテッド filed Critical アフィミューン リミテッド
Publication of JP2017536380A publication Critical patent/JP2017536380A/ja
Publication of JP2017536380A5 publication Critical patent/JP2017536380A5/ja
Priority to JP2021192836A priority Critical patent/JP2022031813A/ja
Application granted granted Critical
Publication of JP6986445B2 publication Critical patent/JP6986445B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017527848A 2014-12-02 2015-12-02 １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 Expired - Fee Related JP6986445B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021192836A JP2022031813A (ja) 2014-12-02 2021-11-29 １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
US62/086,535 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021192836A Division JP2022031813A (ja) 2014-12-02 2021-11-29 １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法

Publications (3)

Publication Number Publication Date
JP2017536380A JP2017536380A (ja) 2017-12-07
JP2017536380A5 JP2017536380A5 (enExample) 2019-01-24
JP6986445B2 true JP6986445B2 (ja) 2021-12-22

Family

ID=56092410

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017527848A Expired - Fee Related JP6986445B2 (ja) 2014-12-02 2015-12-02 １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2021192836A Pending JP2022031813A (ja) 2014-12-02 2021-11-29 １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021192836A Pending JP2022031813A (ja) 2014-12-02 2021-11-29 １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法

Country Status (17)

Country Link
US (1) US10363235B2 (enExample)
EP (2) EP3226873B1 (enExample)
JP (2) JP6986445B2 (enExample)
KR (1) KR20170102879A (enExample)
CN (2) CN112245419A (enExample)
AU (2) AU2015358512B2 (enExample)
BR (1) BR112017011685A2 (enExample)
CA (1) CA2968980A1 (enExample)
ES (1) ES2900593T3 (enExample)
IL (2) IL252431B (enExample)
MA (1) MA41120A (enExample)
MX (2) MX382116B (enExample)
PH (1) PH12017501022B1 (enExample)
RU (2) RU2020115523A (enExample)
SG (2) SG11201704495VA (enExample)
WO (1) WO2016090030A1 (enExample)
ZA (2) ZA201704463B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU2634101A (en) * 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
EP3285072B1 (en) * 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
MX2014004710A (es) 2011-10-19 2014-12-10 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
US20150057216A1 (en) * 2011-12-16 2015-02-26 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法

Also Published As

Publication number Publication date
ZA201804380B (en) 2021-03-31
EP3226873A1 (en) 2017-10-11
JP2017536380A (ja) 2017-12-07
CA2968980A1 (en) 2016-06-09
ES2900593T3 (es) 2022-03-17
MX2017007000A (es) 2017-12-07
ZA201704463B (en) 2018-11-28
HK1245101A1 (zh) 2018-08-24
RU2017122758A (ru) 2019-01-09
PH12017501022A1 (en) 2017-11-27
JP2022031813A (ja) 2022-02-22
SG10202010594WA (en) 2020-12-30
MX2021005080A (es) 2021-06-15
CN107206008A (zh) 2017-09-26
AU2015358512B2 (en) 2021-02-18
BR112017011685A2 (pt) 2018-01-02
WO2016090030A1 (en) 2016-06-09
RU2017122758A3 (enExample) 2019-06-13
SG11201704495VA (en) 2017-06-29
EP3988101A1 (en) 2022-04-27
RU2020115523A (ru) 2021-01-27
RU2721555C2 (ru) 2020-05-20
AU2015358512A1 (en) 2017-07-20
US10363235B2 (en) 2019-07-30
IL252431B (en) 2021-12-01
EP3226873A4 (en) 2018-08-08
IL252431A0 (en) 2017-07-31
PH12017501022B1 (en) 2022-02-16
IL287983A (en) 2022-01-01
AU2021203189A1 (en) 2021-06-10
EP3226873B1 (en) 2021-10-27
US20160184252A1 (en) 2016-06-30
MX382116B (es) 2025-03-13
MA41120A (fr) 2017-10-10
KR20170102879A (ko) 2017-09-12
CN112245419A (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
JP6986445B2 (ja) １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7229285B2 (ja) １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
CA3043284A1 (en) Treatment for fibrosis
KR20240011872A (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
CN107405324A (zh) 包含15‑hepe的组合物和其使用方法
WO2018051230A1 (en) Combination of fxr agonists
EP1997485A1 (en) Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
HK1245101B (en) Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis
CA3100635A1 (en) Combinations comprising tropifexor and cenicriviroc

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211129

R150 Certificate of patent or registration of utility model

Ref document number: 6986445

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees